unknown
Stage
About
Eikonizo develops brain-penetrant and peripherally-restricted small molecule inhibitors targeting HDAC6 to create disease-modifying therapies for neurodegenerative, cardiorenal, and other diseases by improving intracellular transport and proteostasis.
Explore Eikonizo's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.